Nonetheless, during the past 10 years there has been an expansion in the exploration of qEEG and ERP biomarkers of AD, in large part as a result of recent and dramatic improvements in the ease of use of the technology and in access to sufficient computing power and the algorithms necessary for rapid
processing of very complex raw datasets.